85%Confidence
0Views
FDASource
2026-04-21Date
Summary
Fagron's second vancomycin compounding recall for sterility and part detachment issues indicates a pattern of quality failures. This may result in increased regulatory scrutiny for its compounding facilities and loss of pharmacy clientele.
Actionable: Monitor for any FDA enforcement actions against Fagron and assess the risk to its specialized compounding business model.
AI Confidence: 85%
Data Points
firmFagron Compounding Services
classificationClass II
statusOngoing
distributionNationwide in the U.S.A.
productVancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now